Literature DB >> 22539049

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.

Z Reguiai1, J B Bachet, C Bachmeyer, L Peuvrel, M Beylot-Barry, M Bezier, E Boucher, C Chevelle, P Colin, R Guimbaud, L Mineur, M A Richard, P Artru, P Dufour, J M Gornet, E Samalin, R J Bensadoun, M Ychou, T André, B Dreno, O Bouché.   

Abstract

PURPOSE: Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work was to draft an algorithm for the optimised management of this skin toxicity.
METHODS: This algorithm was built in three steps under the responsibility of a steering committee. Step I: a systematic literature analysis (SLA) has been performed. Step II: the collection of information about practices was performed through a questionnaire.These questions were asked during regional meetings to which oncologists, gastro-enterologists, radiotherapists, and dermatologists were invited. Step III: a final meeting was organised involving the bibliography group and the steering committee and regional scientific committees for proposing a final algorithm.
RESULTS: Step I: 14 publications were selected to evaluate the use of cyclines as curative or prophylactic treatment of the folliculitis induced by EGFR inhibitors. Nineteen publications were retained for the topical treatment of the folliculitis. Forty-six articles were selected for the management of the cutaneous lesions in link with appendages and 12 for xerosis and pruritus. Step II: 96 delegates attended the seven regional meetings and 67 questionnaires were analysed. Step III: a final algorithm was proposed on the basis of the conclusions of the first two steps and expert opinions present at this final meeting. The different propositions were unanimously approved by the 14 experts who voted.
CONCLUSIONS: This multidisciplinary study summarising published data and current practices produced a therapeutic algorithm, which should facilitate the standardised, optimised management of skin toxicity associated with EGFR inhibitors in France.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539049     DOI: 10.1007/s00520-012-1451-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  28 in total

Review 1.  Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.

Authors:  Lindy P Fox
Journal:  Oncology (Williston Park)       Date:  2006-04       Impact factor: 2.990

Review 2.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

Authors:  Jenny C Hu; Parrish Sadeghi; Lauren C Pinter-Brown; Sharona Yashar; Melvin W Chiu
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

3.  Cetuximab-induced acne.

Authors:  Emmanuel Molinari; Julie De Quatrebarbes; Thierry André; Sélim Aractingi
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

Review 4.  The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.

Authors:  Siegfried Segaert; Josep Tabernero; Olivier Chosidow; Thomas Dirschka; Joern Elsner; Luca Mancini; Tim Maughan; Jean-Fran Ois Morere; Armando Santoro; Alberto Sobrero; Eric Van Cutsem; Alison Layton
Journal:  J Dtsch Dermatol Ges       Date:  2005-08       Impact factor: 5.584

5.  Clinical management of EGFRI dermatologic toxicities: US perspective.

Authors:  Mario E Lacouture; Jonathan Cotliar; Edith P Mitchell
Journal:  Oncology (Williston Park)       Date:  2007-10       Impact factor: 2.990

6.  Clinical management of EGFRI dermatologic toxicities: the European perspective.

Authors:  Siegfried Segaert; Eric Van Cutsem
Journal:  Oncology (Williston Park)       Date:  2007-10       Impact factor: 2.990

7.  Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Authors:  J Bernier; J Bonner; J B Vermorken; R-J Bensadoun; R Dummer; J Giralt; G Kornek; A Hartley; R Mesia; C Robert; S Segaert; K K Ang
Journal:  Ann Oncol       Date:  2007-09-04       Impact factor: 32.976

Review 8.  EGFR inhibitor-associated acneiform folliculitis: assessment and management.

Authors:  Madeleine Duvic
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

9.  Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.

Authors:  C Gridelli; P Maione; D Amoroso; M Baldari; A Bearz; V Bettoli; E Cammilluzzi; L Crinò; F De Marinis; F A Di Pietro; F Grossi; D Innocenzi; G Micali; F V Piantedosi; M Scartozzi
Journal:  Crit Rev Oncol Hematol       Date:  2007-12-20       Impact factor: 6.312

Review 10.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

View more
  9 in total

Review 1.  Management of egfr tki-induced dermatologic adverse events.

Authors:  B Melosky; N B Leighl; J Rothenstein; R Sangha; D Stewart; K Papp
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.

Authors:  In Gyu Hwang; Jung Hun Kang; Sung Yong Oh; Suee Lee; Sung-Hyun Kim; Ki-Hoon Song; Choonhee Son; Min Jae Park; Myung Hee Kang; Hoon Gu Kim; Jeeyun Lee; Young Suk Park; Jong Mu Sun; Hyun Jung Kim; Chan Kyu Kim; Seong Yoon Yi; Joung-Soon Jang; Keunchil Park; Hyo-Jin Kim
Journal:  Support Care Cancer       Date:  2015-06-04       Impact factor: 3.603

3.  Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.

Authors:  René-Jean Bensadoun; Phillipe Humbert; Jean Krutman; Thomas Luger; Raoul Triller; André Rougier; Sophie Seite; Brigitte Dreno
Journal:  Cancer Manag Res       Date:  2013-12-09       Impact factor: 3.989

4.  Prevention and treatment of acute and chronic radiodermatitis.

Authors:  Sophie Seité; René-Jean Bensadoun; Jean-Michel Mazer
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-11-02

Review 5.  The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.

Authors:  Witold Owczarek; Monika Słowińska; Aleksandra Lesiak; Magdalena Ciążyńska; Aldona Maciąg; Elwira Paluchowska; Luiza Marek-Józefowicz; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

6.  A technical appraisal of guidelines for the management of skin rash in patients on chemotherapy and targeted therapy.

Authors:  Fangyuan Zhang; Sumei Lv; Yating Feng; Xuan Yang; Wanmin Qiang
Journal:  BMC Health Serv Res       Date:  2019-10-16       Impact factor: 2.655

7.  Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.

Authors:  Olivier Bouché; Meher Ben Abdelghani; Jean-Luc Labourey; Simon Triby; René-Jean Bensadoun; Thomas Jouary; Gaétan Des Guetz
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

Review 8.  The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients.

Authors:  Alessandro Allegra; Eleonora Di Salvo; Marco Casciaro; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Biomedicines       Date:  2020-12-22

9.  An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study.

Authors:  Véronique Vendrely; Ander Mayor-Ibarguren; Aline Stennevin; Ariadna Ortiz-Brugués
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.